Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children

NCT02153112 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

840

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus

Interventions

BIOLOGICAL: GI.1/GII.4 (15/15)
BIOLOGICAL: GI.1/GII.4 (15/50)
BIOLOGICAL: GI.1/GII.4 (50/50)
BIOLOGICAL: GI.1/GII.4 (50/150)
DRUG: Placebo

Sponsor

Takeda